Evidence map›Paper›PMID 33514021›Full record

ArticleInternational journal of molecular sciences2021

Neuroprotective Effect of Apolipoprotein D in Cuprizone-Induced Cell Line Models: A Potential Therapeutic Approach for Multiple Sclerosis and Demyelinating Diseases.

Eva Martínez-Pinilla, Núria Rubio-Sardón, Rafael Peláez, Enrique García-Álvarez, Eva Del Valle, Jorge Tolivia, Ignacio M Larráyoz, Ana Navarro

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Neuroprotective Role of Cannabinoid CBMolecular neurobiology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Apolipoprotein D as a Potential Biomarker in Neuropsychiatric Disorders.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eva Martínez-PinillaDepartment of Morphology and Cell Biology, University of Oviedo, 33003 Oviedo, Spain.ORCID 0000-0002-0572-0926
Núria Rubio-SardónDepartment of Morphology and Cell Biology, University of Oviedo, 33003 Oviedo, Spain.
Rafael PeláezBiomarkers and Molecular Signaling Group, Neurodegeneration Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0002-4047-6017
Enrique García-ÁlvarezDepartment of Morphology and Cell Biology, University of Oviedo, 33003 Oviedo, Spain.ORCID 0000-0002-8929-9189
Eva Del ValleDepartment of Morphology and Cell Biology, University of Oviedo, 33003 Oviedo, Spain.
Jorge ToliviaDepartment of Morphology and Cell Biology, University of Oviedo, 33003 Oviedo, Spain.ORCID 0000-0001-8984-8849
Ignacio M LarráyozBiomarkers and Molecular Signaling Group, Neurodegeneration Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain.
Ana NavarroDepartment of Morphology and Cell Biology, University of Oviedo, 33003 Oviedo, Spain.ORCID 0000-0001-6206-6505
Universidad de Oviedo · ESCenter for Biomedical Research of La Rioja · ES

Funding

Instituto de Salud Carlos III PI15/00601Miguel Servet contract, Instituto de Salud Carlos III- FEDER CP15/00198
6 · The paper itself

Abstract

Apolipoprotein D (Apo D) overexpression is a general finding across neurodegenerative conditions so the role of this apolipoprotein in various neuropathologies such as multiple sclerosis (MS) has aroused a great interest in last years. However, its mode of action, as a promising compound for the development of neuroprotective drugs, is unknown. The aim of this work was to address the potential of Apo D to prevent the action of cuprizone (CPZ), a toxin widely used for developing MS models, in oligodendroglial and neuroblastoma cell lines. On one hand, immunocytochemical quantifications and gene expression measures showed that CPZ compromised neural mitochondrial metabolism but did not induce the expression of Apo D, except in extremely high doses in neurons. On the other hand, assays of neuroprotection demonstrated that antipsychotic drug, clozapine, induced an increase in Apo D synthesis only in the presence of CPZ, at the same time that prevented the loss of viability caused by the toxin. The effect of the exogenous addition of human Apo D, once internalized, was also able to directly revert the loss of cell viability caused by treatment with CPZ by a reactive oxygen species (ROS)-independent mechanism of action. Taken together, our results suggest that increasing Apo D levels, in an endo- or exogenous way, moderately prevents the neurotoxic effect of CPZ in a cell model that seems to replicate some features of MS which would open new avenues in the development of interventions to afford MS-related neuroprotection.

Indexed as

AnimalsApolipoproteins DCell LineCell SurvivalCuprizoneDemyelinating DiseasesDisease Models, AnimalHumansMiceMultiple SclerosisNeuroprotective AgentsOligodendrogliaReactive Oxygen SpeciesAPOD protein, humanApolipoproteins DCuprizoneNeuroprotective AgentsReactive Oxygen Speciesbreast cystic fluidclozapineendocytosisglianeuronsROS

Identifiers

PMID33514021
PMCPMC7866080
OpenAlexW3123964344

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.